{"cluster": 20, "subcluster": 70, "abstract_summ": "Methods: Tests were carried out using ELISA (total antibodies) and indirect immunofluorescence (IIFA) (IgM & IgG) methods on serial sera from patients confirmed with SARS-CoV-2 infection.We developed a multiplex SARS-CoV-2 antibody immunoassay based on Luminex technology and tested 167 saliva and 324 serum samples, including 134 and 118 negative saliva and serum samples, respectively, collected before the COVID-19 pandemic, and 33 saliva and 206 serum samples from participants with RT-PCR-confirmed SARS-CoV-2 infection.We evaluated SARS-CoV test assays to detect for the presence of antibodies to SARS-CoV-2 and tried to determine the timing of appearance of these antibodies by testing serial sera from these patients.Conclusions: Existing diagnostic assays for SARS-CoV can detect antibodies in patients who were diagnosed with COVID-19.Within the 10-plex SARS-CoV-2 panel, the salivary anti-nucleocapsid (N) protein IgG response resulted in the highest sensitivity for detecting prior SARS-CoV-2 infection (100% sensitivity at \u226510 days post-SARS-CoV-2 symptom onset).", "title_summ": "Antibodies to SARS/CoV-2 in arbitrarily-selected Atlanta residentsCOVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in salivaSARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact personsEarly detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infectionPoor correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjectsSARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors.Cross-reaction of sera from COVID-19 patients with SARS-CoV assays.", "title_abstract_phrases": "More generally, these results support the general utility of sero-surveillance to guide public policy but also highlight the difficulty of discerning if individuals have immunity to SARS/CoV-2.COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in salivaNon-invasive SARS-CoV-2 antibody testing is urgently needed to estimate the incidence and prevalence of SARS-CoV-2 infection at the general population level.Methods: Tests were carried out using ELISA (total antibodies) and indirect immunofluorescence (IIFA) (IgM & IgG) methods on serial sera from patients confirmed with SARS-CoV-2 infection.We developed a multiplex SARS-CoV-2 antibody immunoassay based on Luminex technology and tested 167 saliva and 324 serum samples, including 134 and 118 negative saliva and serum samples, respectively, collected before the COVID-19 pandemic, and 33 saliva and 206 serum samples from participants with RT-PCR-confirmed SARS-CoV-2 infection.Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infectionBACKGROUND: Thousands of medical staff had been infected with SARS-CoV-2 virus with hundreds of deaths reported.Within the 10-plex SARS-CoV-2 panel, the salivary anti-nucleocapsid (N) protein IgG response resulted in the highest sensitivity for detecting prior SARS-CoV-2 infection (100% sensitivity at \u226510 days post-SARS-CoV-2 symptom onset)."}